Antiviral drugs are different from antibiotics. Flu antiviral drugs are different from antiviral drugs used to treat other infectious diseases such as COVID-19. Antiviral drugs prescribed to treat COVID-19 are not approved or authorized to treat flu.
{| class="wikitable sortable"
|+
List of Antiviral Drugs
!Antiviral
!Use
!Manufacturer
!Component
!Type
!Year approved
|-
|Abacavir
|HIV
|ViiV Healthcare
|
|Nucleoside analogue reverse transcriptase inhibitor (NRTI)
|1998
|-
|Acyclovir (Aciclovir)
|Herpes simplex, chickenpox, varicella zoster virus
|GSK
|
|guanosine analogue RTI
|1981
|-
|Adefovir
|Hepatitis B
|Gilead Sciences
|
|RTI
|2002 (FDA), 2003 (EU)
|-
|Amantadine
|Influenza
|
|
|Influenza A virus M2 proton channel antagonist
|1966
|-
|Ampligen
|Avian Influenza
|
|
|Immunomodulatory double-stranded RNA
|2016 (Argentina)
|-
|Amprenavir (Agenerase)
|HIV
|
|
|Protease inhibitor (PI)
|1999 (FDA)
|-
|Atazanavir
|HIV
|
|
|PI
|2015 (FDA)
|-
|Atripla (Efavirenz/emtricitabine/tenofovir)
|HIV
|
|
|
- Efavirenz: Non-nucleoside RTI (NNRTI)
- Emtricitabine: NRTI
- Tenofovir disoproxil: NRTI
|1998
|-
|Baloxavir marboxil (Xofluza)
|Influenza A/B
|
|
|Cap snatching endonuclease inhibitor
|2018
|-
|Biktarvy (Bictegravir/emtricitabine/tenofovir alafenamide)
|HIV
|Gilead Sciences
|
|
- Bictegravir: INSTI
- Emtricitabine: NRTI
- Tenofovir alafenamide: NRTI
|2018
|-
|Boceprevir
|Hepatitis C genotype 1
|Schering-Plough, then Merck Group
|
|Protease inhibitor
|
- FDA approved 2011
- Withdrawn 2015
|-
|Bulevirtide
|Hepatitis D/B
|
|
|Sodium/bile acid cotransporter inactivator
|2020 (EU)
|-
|Cidofovir
|AIDS
|
|
|Viral DNA Polymerase inhibitor
|1996 (FDA)
|-
|Cobicistat (Tybost)
|HIV
|
|
|human CYP3A protein inhibitor
|
|-
|Combivir (Lamivudine/Zidovudine)
|HIV
|
|
|
- Lamivudine: cytidine analogue RTI
- Zidovudine: thymidine analogue RTI
|1997 (FDA)
|-
|Daclatasvir (Daklinza)
|Hepatitis C
|
|
|NS5A inhibitor
|
|-
|Darunavir
|HIV
|
|antiretroviral
|HIV PI
|
|-
|Delavirdine
|HIV
|
|antiretroviral
|NNRTI
|
|-
|Descovy (Emtricitabine/tenofovir alafenamide)
|Hepatitis B
|
|
|
- Emtricitabine: NRTI
- Tenofovir alafenamide: NRTI
|
|-
|Didanosine
|HIV
|
|
|Adenosine analogue RTI
|1991 (FDA)
|-
|Docosanol
|Herpes Simplex
|
|
|Entry inhibitor
|2000 (FDA)
|-
|Dolutegravir
|HIV
|
|
|Integrase inhibitor
|
|-
|Doravirine (Pifeltro)
|HIV
|Merck & Co
|
|NNRTI
|2018 (FDA)
|-
|Edoxudine
|Herpes Simplex
|
|
|Thymidine analogue inhibitor
|
|-
|Efavirenz
|HIV
|Mylan
|
|NNRTI
|1998
|-
|Elvitegravir
|HIV
|Gilead Sciences
|
|Integrase inhibitor
|
- 2012 (Fixed-dose combo Stribild)
- 2014 (single pill)
- 2015 (Genvoya)
|-
|Emtricitabine
|HIV
|Gilead Sciences
|
|NRTI
|2003
|-
|Enfuvirtide
|HIV
|
|
|Entry inhibitor
|2003
|-
|Ensitrelvir
|COVID-19
|Shionogi
|
|3C-like protease inhibitor
|
|-
|Entecavir
|HIV
|
|
|NRTI
|2005
|-
|Etravirine (Intelence)
|HIV
|
|
|NNRTI
|2008
|-
|Famciclovir
|Herpes Zoster
|
|
|Guanosine analogue
|1994
|-
|Fomivirsen
|AIDS
|
|Anti-sense oligonucleotide
|Anti-sense
|
- FDA-licensed in 1998
- Withdrawn in EU (2002), US (2006)
|-
|Fosamprenavir
|HIV
|ViiV Healthcare
|
|Amprenavir pro-drug
|2003 (FDA), 2004 (EMA)
|-
|Foscarnet
|Herpes
|
|
|Pyrophosphate analogue DNA polymerase inhibitor
|1991
|-
|Ganciclovir (Cytovene)
|Cytomegalovirus (CMV)
|
|
|Competitive nucleoside analogue dGTP inhibitor
|1988
|-
|Ibacitabine
|Herpes labialis
|
|
|
|
|-
|Ibalizumab (Trogarzo)
|HIV
|
|
|Entry inhibitor
|2018
|-
|Idoxuridine
|Herpes
|
|
|dU analogue inhibitor
|1962
|-
|Imiquimod
|Genital wart, Basal cell carcinoma, Actinic keratosis
|
|
|Opioid growth factor receptor (OGFr) agonist
|1997
|-
|Inosine pranobex
|Herpes Simplex
|
|
|Thymus hormone immunostimulant
|
|-
|Indinavir
|HIV
|
|
|PI
|1996
|-
|Lamivudine
|HIV
|
|
|cytidine analogue RTI
|
|-
|Letermovir (Prevymis)
|Cytomegalovirus (CMV)
|
|
|
|
|-
|Lopinavir
|HIV
|
|
|
|
|-
|Loviride
|HIV
|
|
|
|
|-
|Maraviroc
|HIV
|
|
|entry inhibitor
|
|-
|Methisazone
|Smallpox
|
|
|
|
|-
|Molnupiravir
|COVID-19
|Merck & Co.
|
|viral RNA polymerase inhibitor
|
|-
|Moroxydine
|Influenza
|
|
|
|
|-
|Nelfinavir
|HIV
|
|
|
|
|-
|Nirmatrelvir/ritonavir (Paxlovid)
|COVID-19
|Pfizer
|
|3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir)
|
|-
|Nevirapine
|HIV
|
|
|non-nucleoside reverse transcriptase inhibitor
|
|-
|Nitazoxanide
|Broad-spectrum antiviral
|
|thiazolide
|
|
|-
|Norvir
|HIV
|
|
|
|
|-
|Oseltamivir (Tamiflu)
|Influenza
|
|
|neuraminidase inhibitor
|
|-
|Peramivir (Rapivab)
|Influenza
|
|
|
|
|-
|Penciclovir
|Herpes
|
|
|
|
|-
|Pleconaril
|Picornavirus
|Schering-Plough
|
|
|
|-
|Podophyllotoxin
|Genital wart
|
|
|
|
|-
|Raltegravir
|HIV
|
|
|Integrase inhibitor
|
|-
|Raphamin
|
|
|
|
|
|-
|Remdesivir
|COVID-19
|
|
|viral RNA polymerase inhibitor
|
|-
|Ribavirin
|Hepatitis C
|
|
|nucleoside analogue reverse transcriptase inhibitor
|
|-
|Rilpivirine (Edurant)
|HIV
|
|
|
|
|-
|Rimantadine
|Influenza A
|
|
|M2 proton channel antagonist
|
|-
|Ritonavir
|HIV
|
|
|HIV-1 protease inhibitor
|
|-
|Saquinavir
|HIV
|
|
|
|
|-
|Simeprevir (Olysio)
|Hepatitis C
|
|
|
|
|-
|Sofosbuvir
|Hepatitis C
|
|
|nucleoside analogue reverse transcriptase inhibitor
|
|-
|Stavudine
|HIV
|
|
|
|
|-
|Taribavirin (Viramidine)
|Hepatitis Syndromes in which Ribavirin is active
|
|
|
|
|-
|Telaprevir
|Hepatitis C
|
|
|
|
|-
|Telbivudine (Tyzeka)
|Hepatitis B
|
|
|
|
|-
|Tenofovir alafenamide
|Hepatitis B
|
|
|
|
|-
|Tenofovir disoproxil
|Hepatitis B, HIV
|
|
|
|
|-
|Tipranavir
|HIV
|
|
|
|
|-
|Trifluridine
|Eyes related Herpes
|
|
|
|
|-
|Trizivir
|HIV
|
|
|
|
|-
|Tromantadine
|Herpes Simplex
|
|
|
|
|-
|Truvada
|HIV
|
|
|
|
|-
|Umifenovir (Arbidol)
|Influenza
|
|
|Hemagglutinin inhibitor
|
|-
|Valaciclovir (Valtrex)
|Herpes Simplex/Zoster
|
|
|
|
|-
|Valganciclovir (Valcyte)
|Cytomegalovirus (CMV)
|
|
|
|
|-
|Vicriviroc
|HIV-1
|Schering-Plough
|
|pyrimidine CCR5 entry inhibitor
|
|-
|Vidarabine
|Herpes Simplex, Varicella Zoster
|
|
|
|
|-
|Zalcitabine
|HIV
|
|
|
|
|-
|Zanamivir (Relenza)
|Influenza A, Influenza B
|
|
|
|
|-
|Zidovudine
|HIV
|
|Antiretroviral
|
|
|}